Purpose: PARP is essential for recognition and repair of DNA damage. In preclinical models,
PARP inhibitors modulate topoisomerase I inhibitor–mediated DNA damage. This phase I …

P-glycoprotein (P-gp, ABCB1) overexpression and enrichment of stem-like cells are linked to
poor prognosis in tumor patients. In this study, we investigated the effect of apatinib, an oral …

The poly (ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient
in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended …

Francesco Lo-Coco speaks to Sebastian Dennis-Beron, Commissioning Editor: Francesco
Lo-Coco is currently a full professor of hematology and head of the Laboratory of Integrated …

6517 Background: Polycythemia rubra vera (PRV) is a myeloproliferative disorder
characterized by panmyelosis. Increased mRNA for c-kit has been demonstrated in CD34+ …

BACKGROUND: The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various
pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with …

Patients with relapsed indolent non-Hodgkin lymphomas (NHL) are typically treated with the
anti-CD20 antibody rituximab, either as monotherapy or immunochemotherapy. Copanlisib …

Purpose: Antineoplastic agents often achieve antitumor activity at the expense of close to
unacceptable toxicity. One potential avenue to improve therapeutic index might combine …

2579 Background: Veliparib is a potent oral PARP1/2 inhibitor. Monotherapy trials with
immediate release formulation veliparib (IR-v) showed antitumor activity in BRCA+ cancers …

Purpose. The significance of vascular endothelial growth factor receptor (VEGFR)‐2 in
numerous solid tumors and acute myeloid leukemia (AML) has been demonstrated, but …